Baseline patient characteristics
| Effectiveness | Tolerability | |||
|---|---|---|---|---|
| Satisfied n=5822 (54.7%) | Unsatisfied n=4824 (45.3%) | Satisfied n=7273 (68.3%) | Unsatisfied n=3373 (31.7%) | |
| Age, years | 58.3±12.6 | 56.7±12.7 | 57.7±12.8 | 57.3±12.4 |
| Female sex | 4273 (73.4%) | 3639 (75.4%) | 5270 (72.5%) | 2642 (78.3%) |
| Disease duration, years | 9.1 (8.6) | 9 (8.7) | 9.3±8.7 | 8.5±8.5 |
| Seropositivity (RF and/or ACPA positive) | 4244 (72.9%) | 3461 (71.6%) | 5338 (73.4%) | 2358 (69.9%) |
| Current smoker | 1600 (27.5%) | 1369 (28.4%) | 1957 (26.9%) | 839 (24.9%) |
| DAS28-ESR <3.2 | 899 (15.4%) | 361 (7.5%) | 939 (12.9%) | 321 (9.5%) |
| 3.2≤ DAS28-ESR <5.1 | 2961 (50.9%) | 2181 (45.4%) | 3595 (48.4%) | 1558 (46.2%) |
| DAS28-ESR ≥5.1 | 1962 (33.7%) | 2272 (47.1%) | 2739 (37.7%) | 1495 (44.3%) |
| Swollen joint count | 4.7±4.1 | 5.5±4.7 | 5.0±4.3 | 5.2±4.5 |
| Tender joint count | 6.8±6.0 | 8.5±6.9 | 7.3±6.2 | 8.3±6.9 |
| Patient global health assessment | 5.1±2.1 | 6.4±1.9 | 5.5±2.1 | 6.2±1.9 |
| Erythrocyte sedimentation rate (mm) | 27.5±20.5 | 29.2±21.7 | 28.4±21.1 | 28.0±20.8 |
| Pain (0–10 scale) | 5.2±2.3 | 6.2±2.0 | 5.5±2.3 | 6.3±2.1 |
| Percentage of full physical function | 70.7±22.3 | 61.8±22.6 | 68.5±22.7 | 62.7±22.8 |
| Number of previous bDMARDs | 0.4±0.8 | 0.5±0.9 | 0.4±0.9 | 0.4±0.9 |
| Number of previous csDMARDs | 1.9±1.0 | 2.2±1.1 | 2.0±1.1 | 1.2±1.1 |
| Current TNFi therapy | 2320 (39.9%) | 2433 (50.5%) | 3119 (42.9%) | 1634 (48.5%) |
| Current other b/tsDMARD therapy | 1336 (22.9%) | 1256 (26.0%) | 1789 (24.6%) | 803 (23.8%) |
| Glucocorticoids (last 6 months) | 3071 (52.8%) | 2934 (60.8%) | 4031 (55.4%) | 1974 (58.5%) |
| Glucocorticoid dose, mg/day (last 6 months) | 6.7±3.3 | 7.4±3.7 | 6.8±3.3 | 7.5±3.8 |
Numbers are expressed as mean±SD or frequencies (n (%)). Frequencies may be rounded due to multiple imputation of missing values.
ACPA, autoimmune anticitrullinated protein antibodies; bDMARDs, biological disease-modifying antirheumatic drugs; csDMARS; conventional synthetic disease-modifying antirheumatic drugs; DAS28-ESR, Disease Activity Score in 28 joints-erythrocyte sedimentation rate; RF, rheumatoid factor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug; TNFi, tumour necrosis factor-alpha inhibitor.